BioConvergence Excellence Cluster
| Reference number | |
| Coordinator | Sahlgrenska Science Park AB |
| Funding from Vinnova | SEK 1 061 540 |
| Project duration | October 2025 - March 2026 |
| Status | Ongoing |
| Venture | Cluster of Excellence for Cutting-Edge Technologies - calls for proposals |
| Call | Visions for world-leading research and innovation in strategic technology areas |
Important results from the project
The planning project established a starting point for a Swedish BioConvergence Excellence Cluster based on ultra-sensitive molecular technologies created in the convergence of biotechnology, AI and quantum technology. We formulated a vision and an implementation plan, based on international benchmarking. The project mobilized national and international actors and created a core group with strengthened collaboration across sectors, which provided a strategic and foundation for the next phase.
Expected long term effects
The planning project has set a direction for how BioConvergence can translate research into scalable innovations. This can enable preventive and proactive diagnostics and efficient healthcare. The EU digital health market is expected to grow fivefold to € 60 billion by 2035, while the global ctDNA/MRD market is projected to exceed USD 5 billion by 2030. In addition, clinical decision support systems could deliver up to €252 billion in cost savings for healthcare systems in the EU.
Approach and implementation
The project was carried out through workshops and dialogues building a shared vision and strengthened collaboration. Stakeholders from across the pentagon; academia, public sector, industry, investors, and entrepreneurs, were introduced to the global best‑practice model for innovation clusters (C. Rangen). Changed call conditions required adaptation, but momentum and engagement were maintained. Dialogue with 7 other excellence clusters has led to synergies. 3 excellent projects were identified.